CA2208852A1 - Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis - Google Patents
Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxisInfo
- Publication number
- CA2208852A1 CA2208852A1 CA002208852A CA2208852A CA2208852A1 CA 2208852 A1 CA2208852 A1 CA 2208852A1 CA 002208852 A CA002208852 A CA 002208852A CA 2208852 A CA2208852 A CA 2208852A CA 2208852 A1 CA2208852 A1 CA 2208852A1
- Authority
- CA
- Canada
- Prior art keywords
- use according
- compound
- phenyl
- treatment
- prophylaxis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Abstract
The present invention provides novel uses of compounds of general formula (I), wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary anmino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis.
Description
CA 022088~2 1997-06-26 W 096/22093 PCT~DK~6/00013 - 1 -5 Use of 3,4-dichenYI chromans for the manufacture of a Dharmaceutical comPosition for vasodilatorv treatment or orochvlaxis FIELD OF THIS INVENTION
10 The present invention relates to the use of compounds of the general formula I for the vasodilatory treatment of patients suffering from, e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome, and prophy-laxis hereof. The present invention also embraces pharmaceutical compo-sitions comprising these compounds and methods of using the com-15 pounds and their pharmaceutical compositions.
BACKGROUND OF THIS INVENTION
.
Vasodilator drugs are used in several conditions involving tissue ischemia with the most important indication being angina pectoris. Atheroscierosis is involved in most cases of angina pectoris. In recent years a number of studies have revealed important information about the effects of estro-gens on the cardiovascular system. Experiments in animals (Haarbo J et al. J Clin Invest 1991; 87:1294-1279) and epidemiologic studies in humans (PEPI trial, JAMA 1995; 273:199-208) have demonstrated that estrogens possess antiatherogenic properties and it has been speculated that the decreased cardiovascular morbidity and mortality seen in women between 35 and 50 compared to men, is due to an intact ovarian func-tion with the production of estrogens. It has also been demonstrated that estrogens possess vasodilator properties, at least when admini-stered in test systems in pharmacological doses. Estrogens and estrogen receptor stimulation may therefore have a dual mechanism which may CA 022088~2 1997-06-26 W 096/22093 PCTADK~6/00013 - 2 -act synergistically on the pathologic mechanisms involved in tissue ischemia .
Recent studies (Writing group for the PEPI trial, JAMA 273:199, 1955) confirm that oral estrogen taken alone or in combination with medroxy-progesterone acetate or micronized progesterone is associated with a beneficial effect on the risk of developing cardiovascular disease. How-ever, estrogen is also known to have adverse effects on endometrium and perhaps breast tissue by increasing the frequency of malignancies in these areas after prolonged treatment.
Thus, there is a need for a new compound which has the beneficial vasodilatory effect of estrogen, but without introducing significant effects on the reproductive tissues.
Centchroman is a non-steroidal compound known to have antiestrogenic activity. It is in use in India as an oral contraceptive (see, for example, Salman et al., U.S. Patent Specification No. 4,447,622; Singh et al., Acta Endocrinol. (Copenh) 126 (1992), 444 - 450; Grubb, Curr.Opin.Ob-stet. Gynecol. 3 (1991), 491 - 495; Sankaran et al., ContraceDtion 9 (1974), 279 - 289; Indian Patent Specification No. 129187). Centchro-man has also been investigated as an anti-cancer agent for treatment of advanced breast cancer (Misra et al., Int. J. Cancer 43 (1989), 781 -783). Recently, centchroman as a racemate has been found potent as a cholesterol lowering pharmaceutical expressed by a significant decrease of the serum concentrations (S.D. Bain et al., J.Min.Bon.Res. 9 (1994), 394).
U.S. patent 5,280,040 describes methods and pharmaceutical composi-tions for reducing bone loss using 3,4-diarylchromans and their pharma-ceutically acceptable salts.
CA 022088~2 1997-06-26 W 096/22093 PCT~DK~6/00013 One object of the present invention is to provide compounds which can effectively be used in the vasodilatory treatment or prophylaxis of e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome.
BRIEF DESCRIPTION OF THIS INVENTION
It has, surprisingly, been found that compounds of the general formula I
as stated in Claim 1 can be used in the vasodilatory treatment or prophy-laxis of e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome.
DETAILED DESCRIPTION OF THIS INVENTION
The present invention is based in part on the discovery that a representa-tive 3,4-diarylchroman, centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-15 [4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl]-7-methoxychroman) is an effective vasodilatory drug against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome, inter alia in rats. Centchroman is a racemic mix-ture. These animal models are generally recognized models of e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome. These data 20 thus indicate that the 3,4-diarylchromans of formula I are useful as therapeutic and preventive agents against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. The above indications relate to mam-mals, including primates such as humans.
25 Within the present invention, compounds of formula I as stated in Claim 1 are administered as vasodilatory drugs against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. Within formula 1, R1, R4 and R5 are individually hydrogen, halogen, trifluoromethyl, lower alkyl, lower . alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually 30 hydrogen or a lower alkyl. As used herein, the term "lower alkyl"
includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-CA 022088~2 1997-06-26 W 096/22093 PCT~DK96/00013 - 4 -butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like. The term "lower alkoxy" includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amyloxy, sec-5 amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3-dimethylbutoxy and the like.
"Halogen" includes chloro, fluoro, bromo and iodo. The tertiary amino radical may be a N,N-dialkylamine such as a N,N-dimethylamino, N,N-diethylamino, N,N-dipropylamino and N,N-dibutylamino or a polymethy-leneimine, e.g., piperidine, pyrrolidine, N-methylpiperazine or morpholine.
10 Herein, the term "(tertiary amino)(lower alkoxy)" is a lower alkoxy group which is substituted by a tertiary amino group. Preferred compounds include those in which R1 is lower alkoxy; R2 and R3 are lower alkyl, especially methyl; R4 is hydrogen; and R5 is (tertiary amino)(lower alkoxy) of the polymethyleneimine type. Within particularly preferred 15 embodiments, R1 is in the 7-position and is lower alkoxy, particularly methoxy; each of R2 and R3 is methyl, R4 is hydrogen, and R5 is in the 4-position and is a (tertiary amino)(lower alkoxy) radical such as 2-(pyrrolidin-1-yl)ethoxy. To be included by this invention are all pharma-ceutically acceptable salts of the mentioned compounds of formula 1.
10 The present invention relates to the use of compounds of the general formula I for the vasodilatory treatment of patients suffering from, e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome, and prophy-laxis hereof. The present invention also embraces pharmaceutical compo-sitions comprising these compounds and methods of using the com-15 pounds and their pharmaceutical compositions.
BACKGROUND OF THIS INVENTION
.
Vasodilator drugs are used in several conditions involving tissue ischemia with the most important indication being angina pectoris. Atheroscierosis is involved in most cases of angina pectoris. In recent years a number of studies have revealed important information about the effects of estro-gens on the cardiovascular system. Experiments in animals (Haarbo J et al. J Clin Invest 1991; 87:1294-1279) and epidemiologic studies in humans (PEPI trial, JAMA 1995; 273:199-208) have demonstrated that estrogens possess antiatherogenic properties and it has been speculated that the decreased cardiovascular morbidity and mortality seen in women between 35 and 50 compared to men, is due to an intact ovarian func-tion with the production of estrogens. It has also been demonstrated that estrogens possess vasodilator properties, at least when admini-stered in test systems in pharmacological doses. Estrogens and estrogen receptor stimulation may therefore have a dual mechanism which may CA 022088~2 1997-06-26 W 096/22093 PCTADK~6/00013 - 2 -act synergistically on the pathologic mechanisms involved in tissue ischemia .
Recent studies (Writing group for the PEPI trial, JAMA 273:199, 1955) confirm that oral estrogen taken alone or in combination with medroxy-progesterone acetate or micronized progesterone is associated with a beneficial effect on the risk of developing cardiovascular disease. How-ever, estrogen is also known to have adverse effects on endometrium and perhaps breast tissue by increasing the frequency of malignancies in these areas after prolonged treatment.
Thus, there is a need for a new compound which has the beneficial vasodilatory effect of estrogen, but without introducing significant effects on the reproductive tissues.
Centchroman is a non-steroidal compound known to have antiestrogenic activity. It is in use in India as an oral contraceptive (see, for example, Salman et al., U.S. Patent Specification No. 4,447,622; Singh et al., Acta Endocrinol. (Copenh) 126 (1992), 444 - 450; Grubb, Curr.Opin.Ob-stet. Gynecol. 3 (1991), 491 - 495; Sankaran et al., ContraceDtion 9 (1974), 279 - 289; Indian Patent Specification No. 129187). Centchro-man has also been investigated as an anti-cancer agent for treatment of advanced breast cancer (Misra et al., Int. J. Cancer 43 (1989), 781 -783). Recently, centchroman as a racemate has been found potent as a cholesterol lowering pharmaceutical expressed by a significant decrease of the serum concentrations (S.D. Bain et al., J.Min.Bon.Res. 9 (1994), 394).
U.S. patent 5,280,040 describes methods and pharmaceutical composi-tions for reducing bone loss using 3,4-diarylchromans and their pharma-ceutically acceptable salts.
CA 022088~2 1997-06-26 W 096/22093 PCT~DK~6/00013 One object of the present invention is to provide compounds which can effectively be used in the vasodilatory treatment or prophylaxis of e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome.
BRIEF DESCRIPTION OF THIS INVENTION
It has, surprisingly, been found that compounds of the general formula I
as stated in Claim 1 can be used in the vasodilatory treatment or prophy-laxis of e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome.
DETAILED DESCRIPTION OF THIS INVENTION
The present invention is based in part on the discovery that a representa-tive 3,4-diarylchroman, centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-15 [4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl]-7-methoxychroman) is an effective vasodilatory drug against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome, inter alia in rats. Centchroman is a racemic mix-ture. These animal models are generally recognized models of e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome. These data 20 thus indicate that the 3,4-diarylchromans of formula I are useful as therapeutic and preventive agents against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. The above indications relate to mam-mals, including primates such as humans.
25 Within the present invention, compounds of formula I as stated in Claim 1 are administered as vasodilatory drugs against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. Within formula 1, R1, R4 and R5 are individually hydrogen, halogen, trifluoromethyl, lower alkyl, lower . alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually 30 hydrogen or a lower alkyl. As used herein, the term "lower alkyl"
includes straight and branched chain alkyl radicals containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-CA 022088~2 1997-06-26 W 096/22093 PCT~DK96/00013 - 4 -butyl, n-amyl, sec-amyl, n-hexyl, 2-ethylbutyl, 2,3-dimethylbutyl and the like. The term "lower alkoxy" includes straight and branched chain alkoxy radicals containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-amyloxy, sec-5 amyloxy, n-hexyloxy, 2-ethylbutoxy, 2,3-dimethylbutoxy and the like.
"Halogen" includes chloro, fluoro, bromo and iodo. The tertiary amino radical may be a N,N-dialkylamine such as a N,N-dimethylamino, N,N-diethylamino, N,N-dipropylamino and N,N-dibutylamino or a polymethy-leneimine, e.g., piperidine, pyrrolidine, N-methylpiperazine or morpholine.
10 Herein, the term "(tertiary amino)(lower alkoxy)" is a lower alkoxy group which is substituted by a tertiary amino group. Preferred compounds include those in which R1 is lower alkoxy; R2 and R3 are lower alkyl, especially methyl; R4 is hydrogen; and R5 is (tertiary amino)(lower alkoxy) of the polymethyleneimine type. Within particularly preferred 15 embodiments, R1 is in the 7-position and is lower alkoxy, particularly methoxy; each of R2 and R3 is methyl, R4 is hydrogen, and R5 is in the 4-position and is a (tertiary amino)(lower alkoxy) radical such as 2-(pyrrolidin-1-yl)ethoxy. To be included by this invention are all pharma-ceutically acceptable salts of the mentioned compounds of formula 1.
2~
It is preferred to use the compounds of formula I in the transconfigura-tion. These compounds may be used as racemic mixtures, or the isolated stereoisomers, e.g. d- or 1- enantiomers, may be used. The trans-d-enantiomers are more preferred.
A particularly preferred compound for use within the present invention is centchroman consisting of l-centchroman and d-centchroman. Probably, I-centchroman has the formula IV
CA 022088~2 1997-06-26 3 PCT/I)K96/00013 ~N
o (IV) ~',~""'V
3 o ~~
10 3,4-diarylchromans are prepared according to known methods, such as those disclosed in U.S. Patent Specification No. 3,340,276 to Carney et al., U.S. Patent Specification No. 3,822,287 to Bolger, and Ray et al., J.Med.Chem. 19 (1976), 276 - 279, the contents of which are incorpo-rated herein by reference. Conversion of the cis isomer to the trans 15 configuration by means of an organometallic base-catalyzed rearrange-ment is disclosed in U.S. Patent Specification No. 3,822,287. The optically active d- and l-enantiomers may be prepared as disclosed by Salman et al. in U.S. Patent Specification No. 4,447,622 (incorporated herein by reference) by forming an optically active acid salt which is 20 subjected to alkaline hydrolysis to produce the desired enantiomer. If R2 is different from R3 and R4 is different from R5, the general formula I
covers 8 optical isomers.
Within the present invention, 3,4-diarylchromans of formula I may be 25 prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, 30 benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like. The acid addition salts may be obtained as the direct CA 022088~2 1997-06-26 W 096/22093 PCT~DK96/00013 - 6 -products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the sait isolated by evaporating the solvent or otherwise separating the salt and solvent.
3,4-diarylchromans of formula I and their salts are useful as vasodilatory drugs within the field of human and veterinary medicine, for example, in the treatment or prophylaxis of patients suffering from e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. For use within the 10 present invention, 3,4-diarylchromans of formula I and their pharmaceuti-cally acceptable salts are formulated with a pharmaceutically acceptable carrier to provide a medicament for parenteral, oral, nasal, rectal, subdermal or intradermal or transdermal administration according to conventional methods. Formulations may further include one or more 15 diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, supposi-tories, liposomes, transdermal patches, controlled release, dermal implants, tablets, etc. One skilled in this art may formulate the com-pounds of formula I in an appropriate manner, and in accordance with 20 accepted practices, such as those disclosed in Reminaton's Pharmaceuti-cal Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990.
-Oral administration is preferred. Thus, the active compound of formula Iis prepared in a form suitable for oral administration, such as a tablet or 25 capsule. Typically, a pharmaceutically acceptable salt of the compound of formula I is combined with a carrier and moulded into a tablet. Suit-able carriers in this regard include starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like. Such compositions may further include one or more auxiliary substances, such as wetting 30 agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
Pharmaceutical compositions containing a compound of formula I may be CA 022088~2 1997-06-26 administered one or more times per day or week. An effective amount of such a pharmaceutical composition is the amount that provides a clinical-ly significant vasodilatory effect against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. Such amounts will depend, in part, on 5 the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art.
The pharmaceutical compositions containing a compound of formula I
may be administered in unit dosage form one or more times per day or 10 week. In the alternative, they may be provided as controlled release formulations suitable for dermal implantation. Implants are formulated to provide release of active compound over the desired period of time, which can be up to several years. Controlled-release formulations are disclosed by, for example, Sanders et al., J.Pharm.Sci. 73 (1964), 1294 - 1297, 1984; U.S. Patent Specification No. 4,489,056; and U.S.
Patent Specification No. 4,210,644, which are incorporated herein by reference.
Examples of preferred compounds of formula I are centchroman as a 20 racemic mixture and as l-centchroman and d-centchroman. Furthermore, 3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl]-7-hydroxychroman is a preferred compound. A more preferred compound is d-3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl)-7-methoxychroman The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protec-tion.
30 The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
CA 022088~2 1997-06-26 W 096/22093 PCTMDK~6/00013 EXAMPLE
The effects of d-centchroman on arterial contractility was investigated in an in vitro system using thoracic aorta rings from female Wistar rats. The rats were killed and the thoracic aorta excised from the body and posi-tioned in a small organ bath in which it was possible to measure contrac-tility via a force transducer. Arterial contraction was induced by bathing the aorta ring in a solution containing 300 nM phenyiephrine to which was added either increasing doses of vehicle (DMS0), estrogen or d-1 0 centchroman.
The data revealed (table 1 ) that d-centchroman possessed the ability to dilate a precontracted aorta ring. d-centchroman was a potent vasodilator with an EC50 value of 13,uM approximately 5 times as potent as estrogen. Subsequent experiments in which the endothelial nitric oxide synthesis was blocked by l-NAME showed a rightward shift of the dose-response curve with a factor of about 10. These data indicated that at least some of the relaxing effect of d-centchroman is dependent on the synthesis of N0 (endothelium derived relaxing factor, EDRF).
Table 1. Dose-response characteristics of compounds Compound EC50 (~M) %Efficacy 1 7-13-estradiol 60 57 d-centchroman 13 98
It is preferred to use the compounds of formula I in the transconfigura-tion. These compounds may be used as racemic mixtures, or the isolated stereoisomers, e.g. d- or 1- enantiomers, may be used. The trans-d-enantiomers are more preferred.
A particularly preferred compound for use within the present invention is centchroman consisting of l-centchroman and d-centchroman. Probably, I-centchroman has the formula IV
CA 022088~2 1997-06-26 3 PCT/I)K96/00013 ~N
o (IV) ~',~""'V
3 o ~~
10 3,4-diarylchromans are prepared according to known methods, such as those disclosed in U.S. Patent Specification No. 3,340,276 to Carney et al., U.S. Patent Specification No. 3,822,287 to Bolger, and Ray et al., J.Med.Chem. 19 (1976), 276 - 279, the contents of which are incorpo-rated herein by reference. Conversion of the cis isomer to the trans 15 configuration by means of an organometallic base-catalyzed rearrange-ment is disclosed in U.S. Patent Specification No. 3,822,287. The optically active d- and l-enantiomers may be prepared as disclosed by Salman et al. in U.S. Patent Specification No. 4,447,622 (incorporated herein by reference) by forming an optically active acid salt which is 20 subjected to alkaline hydrolysis to produce the desired enantiomer. If R2 is different from R3 and R4 is different from R5, the general formula I
covers 8 optical isomers.
Within the present invention, 3,4-diarylchromans of formula I may be 25 prepared in the form of pharmaceutically acceptable salts, especially acid-addition salts, including salts of organic acids and mineral acids.
Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, tartaric acid, citric acid, 30 benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like. The acid addition salts may be obtained as the direct CA 022088~2 1997-06-26 W 096/22093 PCT~DK96/00013 - 6 -products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the sait isolated by evaporating the solvent or otherwise separating the salt and solvent.
3,4-diarylchromans of formula I and their salts are useful as vasodilatory drugs within the field of human and veterinary medicine, for example, in the treatment or prophylaxis of patients suffering from e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. For use within the 10 present invention, 3,4-diarylchromans of formula I and their pharmaceuti-cally acceptable salts are formulated with a pharmaceutically acceptable carrier to provide a medicament for parenteral, oral, nasal, rectal, subdermal or intradermal or transdermal administration according to conventional methods. Formulations may further include one or more 15 diluents, fillers, emulsifiers, preservatives, buffers, excipients, etc. and may be provided in such forms as liquids, powders, emulsions, supposi-tories, liposomes, transdermal patches, controlled release, dermal implants, tablets, etc. One skilled in this art may formulate the com-pounds of formula I in an appropriate manner, and in accordance with 20 accepted practices, such as those disclosed in Reminaton's Pharmaceuti-cal Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990.
-Oral administration is preferred. Thus, the active compound of formula Iis prepared in a form suitable for oral administration, such as a tablet or 25 capsule. Typically, a pharmaceutically acceptable salt of the compound of formula I is combined with a carrier and moulded into a tablet. Suit-able carriers in this regard include starch, sugars, dicalcium phosphate, calcium stearate, magnesium stearate and the like. Such compositions may further include one or more auxiliary substances, such as wetting 30 agents, emulsifiers, preservatives, stabilizers, colouring additives, etc.
Pharmaceutical compositions containing a compound of formula I may be CA 022088~2 1997-06-26 administered one or more times per day or week. An effective amount of such a pharmaceutical composition is the amount that provides a clinical-ly significant vasodilatory effect against e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome. Such amounts will depend, in part, on 5 the particular condition to be treated, age, weight, and general health of the patient, and other factors evident to those skilled in the art.
The pharmaceutical compositions containing a compound of formula I
may be administered in unit dosage form one or more times per day or 10 week. In the alternative, they may be provided as controlled release formulations suitable for dermal implantation. Implants are formulated to provide release of active compound over the desired period of time, which can be up to several years. Controlled-release formulations are disclosed by, for example, Sanders et al., J.Pharm.Sci. 73 (1964), 1294 - 1297, 1984; U.S. Patent Specification No. 4,489,056; and U.S.
Patent Specification No. 4,210,644, which are incorporated herein by reference.
Examples of preferred compounds of formula I are centchroman as a 20 racemic mixture and as l-centchroman and d-centchroman. Furthermore, 3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl]-7-hydroxychroman is a preferred compound. A more preferred compound is d-3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1 -yl)ethoxy)phenyl)-7-methoxychroman The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protec-tion.
30 The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
CA 022088~2 1997-06-26 W 096/22093 PCTMDK~6/00013 EXAMPLE
The effects of d-centchroman on arterial contractility was investigated in an in vitro system using thoracic aorta rings from female Wistar rats. The rats were killed and the thoracic aorta excised from the body and posi-tioned in a small organ bath in which it was possible to measure contrac-tility via a force transducer. Arterial contraction was induced by bathing the aorta ring in a solution containing 300 nM phenyiephrine to which was added either increasing doses of vehicle (DMS0), estrogen or d-1 0 centchroman.
The data revealed (table 1 ) that d-centchroman possessed the ability to dilate a precontracted aorta ring. d-centchroman was a potent vasodilator with an EC50 value of 13,uM approximately 5 times as potent as estrogen. Subsequent experiments in which the endothelial nitric oxide synthesis was blocked by l-NAME showed a rightward shift of the dose-response curve with a factor of about 10. These data indicated that at least some of the relaxing effect of d-centchroman is dependent on the synthesis of N0 (endothelium derived relaxing factor, EDRF).
Table 1. Dose-response characteristics of compounds Compound EC50 (~M) %Efficacy 1 7-13-estradiol 60 57 d-centchroman 13 98
Claims (22)
1. The use of compounds of the general formula I
(I) wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition showing a vasodilatory effect.
(I) wherein R1, R4 and R5 are individually hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino)(lower alkoxy); and R2 and R3 are individually hydrogen or lower alkyl, or as a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the manufacture of a pharmaceutical composition showing a vasodilatory effect.
2. The use according to claim 1 for the treatment or prophylaxis of cerebral ischaemia.
3. The use according to claim 1 for the treatment or prophylaxis of angina pectoris.
4. The use according to claim 1 for the treatment or prophylaxis of Raynard's syndrome.
5. The use according to anyone of claims 1-4 wherein said compound has the general formula III:
(III) wherein R1, R2, R3, R4 and R5 each has the meaning stated in Claim 1.
(III) wherein R1, R2, R3, R4 and R5 each has the meaning stated in Claim 1.
6. The use according to any one of the preceding claims 1-5 wherein R1 is lower alkoxy, preferably methoxy.
7. The use according to any one of the preceding claims wherein R2 is lower alkyl, preferably methyl.
8. The use according to any one of the preceding claims wherein R3 is lower alkyl, preferably methyl.
9. The use according to any one of the preceding claims wherein R4 is hydrogen.
10. The use according to any one of the preceding claims wherein R5 is (tertiary amino)(lower alkoxy), preferably 2-(pyrrolidin-1-yl)ethoxy.
11. The use according to any one of the preceding claims wherein said compound is a stereoisomer, e.g. an isolated d- or l-enantiomer.
12. The use according to anyone of the preceding claims wherein said compound is an isolated d-enantiomer.
13. The use according to any one of the preceding claims 1-4 wherein said compound is 3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman.
14. The use according to the preceding claim wherein said compound is an isolated d- or l-enantiomer of 3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman.
15. The use according to claim 14 wherein said compound is d-3,4-trans-2,2-dimethyl-3-phenyl-4-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-7-methoxychroman.
16. The use according to any one of the preceding claims wherein said composition is in a form suitable for oral administration.
17. The use according to any one of the preceding claims wherein said compound is administered as a dose in a range from about 0.001 to 75, preferably in a range from 0.01 to 75, more preferably in the range from about 0.01 to 50, and especially in the range from about 0.1 to 25, mg/kg patient per day.
18. The use according to any one of the preceding claims wherein said composition is administered one or more times per day or week.
19. The use according to any one of the preceding claims wherein said composition is in the form of a dermal implant.
20. Method for the vasodilatory treatment and prophylaxis of e.g.
cerebral ischaemia, angina pectoris or Raynaud's syndrome, comprising administering to a patient a clinically effective amount of compounds of formula I stated to be used in any one of the preceding use claims, or a pharmaceutically acceptable salt thereof.
cerebral ischaemia, angina pectoris or Raynaud's syndrome, comprising administering to a patient a clinically effective amount of compounds of formula I stated to be used in any one of the preceding use claims, or a pharmaceutically acceptable salt thereof.
21. A vasodilatory method of treating or preventing e.g. cerebral ischaemia, angina pectoris or Raynaud's syndrome, which method comprises administering a clinically effective amount of a compound of formula I or a salt thereof and pharmaceutically acceptable compositions containing such a compound, to a patient in need of such a treatment.
22. Any novel feature or combination of features described herein.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK0067/95 | 1995-01-20 | ||
| DK6795 | 1995-01-20 | ||
| DK77595 | 1995-06-30 | ||
| DK0775/95 | 1995-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2208852A1 true CA2208852A1 (en) | 1996-07-25 |
Family
ID=26063230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002208852A Abandoned CA2208852A1 (en) | 1995-01-20 | 1996-01-10 | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5886021A (en) |
| EP (1) | EP0804188A1 (en) |
| JP (1) | JPH10513154A (en) |
| KR (1) | KR19980701548A (en) |
| CN (1) | CN1168100A (en) |
| AU (1) | AU4329196A (en) |
| BR (1) | BR9606767A (en) |
| CA (1) | CA2208852A1 (en) |
| CZ (1) | CZ211897A3 (en) |
| HU (1) | HUP9800297A3 (en) |
| IL (1) | IL116827A (en) |
| NO (1) | NO973341D0 (en) |
| WO (1) | WO1996022093A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| CN101056868B (en) | 2004-09-21 | 2012-05-02 | 马休爱德华兹股份有限公司 | Substituted chroman derivatives, medicaments and use in therapy |
| CA2816319C (en) | 2010-11-01 | 2020-06-30 | Marshall Edwards, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| SG11201604490SA (en) | 2014-02-07 | 2016-07-28 | Novogen ltd | Functionalised benzopyran compounds and use thereof |
| CA2974123C (en) | 2015-02-02 | 2023-08-01 | Mei Pharma, Inc. | Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340276A (en) * | 1964-04-01 | 1967-09-05 | Ciba Geigy Corp | 3, 4-diphenyl-chromans |
| US3822287A (en) * | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
| US4447622A (en) * | 1981-09-22 | 1984-05-08 | Council Of Scientific And Industrial Research Rafi Marg | Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof |
| US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
-
1996
- 1996-01-10 BR BR9606767A patent/BR9606767A/en unknown
- 1996-01-10 CA CA002208852A patent/CA2208852A1/en not_active Abandoned
- 1996-01-10 WO PCT/DK1996/000013 patent/WO1996022093A1/en not_active Application Discontinuation
- 1996-01-10 JP JP8521978A patent/JPH10513154A/en active Pending
- 1996-01-10 AU AU43291/96A patent/AU4329196A/en not_active Abandoned
- 1996-01-10 HU HU9800297A patent/HUP9800297A3/en unknown
- 1996-01-10 CZ CZ972118A patent/CZ211897A3/en unknown
- 1996-01-10 EP EP96900094A patent/EP0804188A1/en not_active Withdrawn
- 1996-01-10 CN CN96191514A patent/CN1168100A/en active Pending
- 1996-01-10 KR KR1019970704939A patent/KR19980701548A/en not_active Application Discontinuation
- 1996-01-19 IL IL11682796A patent/IL116827A/en active IP Right Grant
-
1997
- 1997-07-18 NO NO973341A patent/NO973341D0/en unknown
- 1997-08-18 US US08/912,802 patent/US5886021A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR9606767A (en) | 1997-12-30 |
| HUP9800297A3 (en) | 1999-12-28 |
| KR19980701548A (en) | 1998-05-15 |
| CZ211897A3 (en) | 1997-12-17 |
| NO973341L (en) | 1997-07-18 |
| AU4329196A (en) | 1996-08-07 |
| IL116827A0 (en) | 1996-05-14 |
| HUP9800297A2 (en) | 1998-12-28 |
| US5886021A (en) | 1999-03-23 |
| EP0804188A1 (en) | 1997-11-05 |
| CN1168100A (en) | 1997-12-17 |
| JPH10513154A (en) | 1998-12-15 |
| IL116827A (en) | 1999-11-30 |
| WO1996022093A1 (en) | 1996-07-25 |
| NO973341D0 (en) | 1997-07-18 |
| MX9705379A (en) | 1997-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5726202A (en) | Benign prostatic hypertrophy | |
| US5883118A (en) | Prostatic carcinoma | |
| AU693628B2 (en) | Use of 3,4-diphenylchromans | |
| EP0873120A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms | |
| KR19990077157A (en) | Use of Centroman L-Enantiomers for the Preparation of Pharmaceutical Compositions for the Treatment or Prevention of Breast Cancer | |
| CA2208859A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment | |
| US5886021A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis | |
| US6008242A (en) | Use of 1-centchroman for the manufacture of a pharmaceutical composition for the treatment of obesity | |
| WO1998033499A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women | |
| US5919812A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic or physiologic gynaecomastia | |
| US5780502A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome | |
| WO1998033500A1 (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting senescence-associated motor impairment | |
| MXPA97005379A (en) | Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for treatment or profilaxis vasodilatad | |
| MXPA97005378A (en) | Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of the obesi | |
| MXPA97005214A (en) | Use of the 3,4-difenil-chromanos for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arterioesclerosis or for anti-treatment | |
| WO1999048497A1 (en) | USE OF 3,4-DIPHENYLCHROMANS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR LOWERING PLASMA LEVELS OF Lp(a) IN A HUMAN OR SUB-HUMAN PRIMATE | |
| MXPA97005218A (en) | Use of the 3,4-difenil-chromians for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of idiopathic gynecomassia or physiology | |
| KR19980701382A (en) | Use of 3,4-diphenylchroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia, or atherosclerosis or for the treatment of anticoagulants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20010110 |